The overall goals of the Yale SPORE in Skin Cancer (YSPORE) are to improve prevention, diagnosis and treatment of melanomas by performing translational studies in four subjects: a) (Genomic sunlight dosimeters for melanoma prevention (Project 1);b) The B7-H1/PD-1 pathway in melanoma immunity (Project 2);c) Molecular diversity of melanomas and response to targeted (Project 3);and d) The RACil pathway as a target for melanoma therapy (Project 4). The program includes Developmental Research and Career Development Programs, Biospecimen Resource and Bioinformatics/Biostatistics Cores that support the translational research needs of all investigators in the YSPORE. The YSPORE is led by an Administration Core that coordinates and manages the program on a daily basis. One of the overriding themes of the YSPORE is to reveal biomarkers and targets for therapy based on Information from Next-Generation (Next-Gen) DNA sequencing, genomics and proteomics analyses. This approach will be used to identify: 1) regions of the genome that are sensitive indicators of long-term accumulation of DNA damage and mutations resulting from sunlight exposure;and 2) the molecular basis of resistance of melanomas to targeted therapy with BRAF inhibitors (BRAFi). We will use structure function analyses to identify druggable targets in resistant cells (Project 3) and in a novel RAC1 pathway that we have identified in melanoma (Project 4). Project 2 is dedicated to one of the most promising immunotherapy for melanoma, anti PD-1, and is focused on tumor/stroma interactions to reveal mechanism of evasion of cancer immunity. The studies in this project should have direct impact for current development of B7-H1/PD-1 blockade as a novel and promising approach for melanoma therapy. The expected translational outcomes of the program are: 1) Development of biological indicators for sun exposure risk to be used in melanoma prevention;2) The identification of predictive biomarkers for therapeutic blockade of the PD-1/PD-L1 pathway and the role of this pathway in resistance to other types of immunotherapy, leading to potentially more effective combination immunotherapy;3) The development of molecular tests that will guide treatment for BRAFi;4) The classification of melanoma according to therapeutic options based on mutations in 'driver'pathway;5) identification of small molecule that can target the """"""""RAC1 pathway"""""""";6) The implementation of new national initiatives such as the CaTISSUE, The Cancer Genome Atlas (TCGA) and the MRF National Consortium for melanoma clinical trials.

Public Health Relevance

The studies will address major questions in melanoma: 1) Can cumulative carcinogenic sunlight exposure can be measured as DNA damage and mutations in individual's skin? 2) Can melanomas be classified based on mutations in specific networks? 3) Are there molecular markers that can predict a patient's response to targeted and immunotherapies? 4) Is the newly discovered RAC1 pathway can become an alternative therapeutic target?

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-0 (M1))
Program Officer
Agarwal, Rajeev K
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Yale University
Schools of Medicine
New Haven
United States
Zip Code
Brash, Douglas E (2016) UV-induced Melanin Chemiexcitation: A New Mode of Melanoma Pathogenesis. Toxicol Pathol 44:552-4
Premi, Sanjay; Brash, Douglas E (2016) Chemical excitation of electrons: A dark path to melanoma. DNA Repair (Amst) 44:169-77
Jiang, Yu; Shi, Xingjie; Zhao, Qing et al. (2016) Integrated analysis of multidimensional omics data on cutaneous melanoma prognosis. Genomics 107:223-30
Cyrus, Nika; Mai-Anh Bui, Christine; Yao, Xiaopan et al. (2016) Density and Polarization States of Tumor-Associated Macrophages in Human Cutaneous Squamous Cell Carcinomas Arising in Solid Organ Transplant Recipients. Dermatol Surg 42 Suppl 1:S18-23
Robles-Espinoza, Carla Daniela; Roberts, Nicola D; Chen, Shuyang et al. (2016) Germline MC1R status influences somatic mutation burden in melanoma. Nat Commun 7:12064
Gibson, Juliet F; Huang, Jing; Liu, Kristina J et al. (2016) Cutaneous T-cell lymphoma (CTCL): Current practices in blood assessment and the utility of T-cell receptor (TCR)-Vβ chain restriction. J Am Acad Dermatol 74:870-7
Wang, Xuefeng; Chen, Mengjie; Yu, Xiaoqing et al. (2016) Global copy number profiling of cancer genomes. Bioinformatics 32:926-8
Wang, Yu; Zhao, Yinjun; Ma, Shuangge (2016) Racial differences in six major subtypes of melanoma: descriptive epidemiology. BMC Cancer 16:691
Weed, Jason; Gibson, Juliet; Lewis, Julia et al. (2016) FISH Panel for Leukemic CTCL. J Invest Dermatol :
Halaban, Ruth; Krauthammer, Michael (2016) RASopathy Gene Mutations in Melanoma. J Invest Dermatol 136:1755-9

Showing the most recent 10 out of 134 publications